{"id":611,"date":"2020-03-30T08:55:01","date_gmt":"2020-03-30T08:55:01","guid":{"rendered":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/?page_id=611"},"modified":"2023-02-02T13:49:25","modified_gmt":"2023-02-02T13:49:25","slug":"reserved-technology-capacity-case-study","status":"publish","type":"page","link":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/","title":{"rendered":"Reserved Technology Capacity Case Study"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>At Almac, we realise our client partners face a variety of business challenges from changing clinical trial plans to forecasting difficulties particularly for specialised medicines and orphan drug products and as such, we differentiate ourselves by offering the flexibility that clients need.<\/p>\n\n\n\n<p>Working with our client partners, we provide tailored solutions to meet their unique development, manufacturing and packaging outsourcing needs.<\/p>\n\n\n\n<p>This case study is an example of our \u2018Reserved Technology Capacity\u2019 business model and provides an overview of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The strategic partnership established between Almac and a global Big Pharma company<\/li>\n\n\n\n<li>How moving from a transactional fee for service model benefited our client partner allowing them to have dedicated capacity on key technology to support their clinical trials<\/li>\n<\/ul>\n\n\n\n<p>If you require any further information, please&nbsp;<a href=\"https:\/\/www.almacgroup.com\/pharmaceutical-development\/contact-us\">contact us<\/a>&nbsp;directly.&nbsp;<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\"><div class=\"wp-block-image\">\n<figure class=\"alignright size-large\"><img decoding=\"async\" width=\"212\" height=\"300\" data-src=\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png\" alt=\"\" class=\"wp-image-615 lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" style=\"--smush-placeholder-width: 212px; --smush-placeholder-aspect-ratio: 212\/300;\" \/><noscript><img decoding=\"async\" width=\"212\" height=\"300\" src=\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png\" alt=\"\" class=\"wp-image-615\"\/><\/noscript><\/figure><\/div>\n\n\n<p><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>At Almac, we realise our client partners face a variety of business challenges from changing clinical trial plans to forecasting difficulties particularly for specialised medicines and orphan drug products and as such, we differentiate ourselves by offering the flexibility that clients need. Working with our client partners, we provide tailored solutions to meet their unique [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-611","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.3.1 (Yoast SEO v26.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Reserved Technology Capacity Case Study - Pharmaceutical Development<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reserved Technology Capacity Case Study\" \/>\n<meta property=\"og:description\" content=\"At Almac, we realise our client partners face a variety of business challenges from changing clinical trial plans to forecasting difficulties particularly for specialised medicines and orphan drug products and as such, we differentiate ourselves by offering the flexibility that clients need. Working with our client partners, we provide tailored solutions to meet their unique [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharmaceutical Development\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-02T13:49:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/\",\"url\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/\",\"name\":\"Reserved Technology Capacity Case Study - Pharmaceutical Development\",\"isPartOf\":{\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png\",\"datePublished\":\"2020-03-30T08:55:01+00:00\",\"dateModified\":\"2023-02-02T13:49:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#primaryimage\",\"url\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png\",\"contentUrl\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png\",\"width\":212,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reserved Technology Capacity Case Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#website\",\"url\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/\",\"name\":\"Pharmaceutical Development\",\"description\":\"Pharmaceutical Development\",\"publisher\":{\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#organization\",\"name\":\"Almac Group Ltd\",\"url\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/04\/almac-logo-with-strapline.jpg\",\"contentUrl\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/04\/almac-logo-with-strapline.jpg\",\"width\":643,\"height\":296,\"caption\":\"Almac Group Ltd\"},\"image\":{\"@id\":\"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Reserved Technology Capacity Case Study - Pharmaceutical Development","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/","og_locale":"en_GB","og_type":"article","og_title":"Reserved Technology Capacity Case Study","og_description":"At Almac, we realise our client partners face a variety of business challenges from changing clinical trial plans to forecasting difficulties particularly for specialised medicines and orphan drug products and as such, we differentiate ourselves by offering the flexibility that clients need. Working with our client partners, we provide tailored solutions to meet their unique [&hellip;]","og_url":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/","og_site_name":"Pharmaceutical Development","article_modified_time":"2023-02-02T13:49:25+00:00","og_image":[{"url":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/","url":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/","name":"Reserved Technology Capacity Case Study - Pharmaceutical Development","isPartOf":{"@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#primaryimage"},"image":{"@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png","datePublished":"2020-03-30T08:55:01+00:00","dateModified":"2023-02-02T13:49:25+00:00","breadcrumb":{"@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#primaryimage","url":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png","contentUrl":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/03\/Reserved-Capacity-Case-Study-Cover-212x300-1.png","width":212,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/reserved-technology-capacity-case-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/"},{"@type":"ListItem","position":2,"name":"Reserved Technology Capacity Case Study"}]},{"@type":"WebSite","@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#website","url":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/","name":"Pharmaceutical Development","description":"Pharmaceutical Development","publisher":{"@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#organization","name":"Almac Group Ltd","url":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#\/schema\/logo\/image\/","url":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/04\/almac-logo-with-strapline.jpg","contentUrl":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-content\/uploads\/sites\/5\/2020\/04\/almac-logo-with-strapline.jpg","width":643,"height":296,"caption":"Almac Group Ltd"},"image":{"@id":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-json\/wp\/v2\/pages\/611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-json\/wp\/v2\/comments?post=611"}],"version-history":[{"count":14,"href":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-json\/wp\/v2\/pages\/611\/revisions"}],"predecessor-version":[{"id":1008,"href":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-json\/wp\/v2\/pages\/611\/revisions\/1008"}],"wp:attachment":[{"href":"https:\/\/www.almacgroup.com\/pharmaceutical-drug-product-development\/wp-json\/wp\/v2\/media?parent=611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}